Medical Microinstruments (MMI), a robotics firm devoted to rising remedy choices and enhancing medical outcomes for sufferers with advanced situations, has raised $110 million in Collection C financing.
The spherical, led by Constancy Administration & Analysis Firm, marks the biggest ever funding in microsurgery innovation.
The funds will assist commercialization of the Symani Surgical System in high-growth markets and continued funding in research that generate medical proof and allow indication enlargement.
Investments will even speed up superior know-how capabilities and allow MMI to scale its operational capabilities globally.
MMI and its current buyers, all of whom contributed to the Collection C financing, see appreciable alternative for fast development.
The corporate tasks the marketplace for eligible robotic microsurgical procedures will develop from 3 million to 22 million yearly by 2028, pushed primarily by technological developments and indication enlargement.
Mark Toland, CEO of MMI, says: “In opposition to a backdrop of plateauing investments in medical robotics, this assist builds on our confidence in a brand new, much less invasive resolution for open surgical procedure, a major market that may profit from the smallest wristed microinstruments.
“Our Symani Surgical System is uniquely positioned to broaden affected person entry to care by accelerating the variety of surgeons capable of carry out advanced, delicate procedures.
“With the assist of our buyers, we’ll proceed to advance our know-how by means of a rising physique of medical proof and expanded hospital partnerships.”
The Symani Surgical System is a first-of-its-kind robotic know-how that uniquely addresses the size and complexities of microsurgery and supermicrosurgery.
By permitting surgeons to copy the pure actions of the human hand on the micro scale, it might probably broaden remedy choices for sufferers in want of soppy tissue, open surgical procedures, comparable to free flap reconstructions, lymphatic surgical procedure, and trauma replantations.
It’s designed to assist restore high quality of life for extra sufferers, speed up the variety of surgeons capable of push the boundaries of advanced procedures for delicate anatomy, and allow hospitals to broaden their open surgical packages.
MMI has raised over $200 million in funding thus far. In 2022, it closed a Collection B financing spherical to propel development.
The funding was allotted to assist broaden indications and assist ongoing commercialization efforts for the Symani Surgical System in Europe, the place it acquired CE mark in 2019, speed up plans to commercialize within the US and Asia-Pacific, and advance medical analysis.